Last reviewed · How we verify
Combination of SH003 and Docetaxel
Combination of SH003 and Docetaxel is a Small molecule drug developed by Kyunghee University Medical Center. It is currently in Phase 1 development.
At a glance
| Generic name | Combination of SH003 and Docetaxel |
|---|---|
| Sponsor | Kyunghee University Medical Center |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Combination of SH003 and Docetaxel CI brief — competitive landscape report
- Combination of SH003 and Docetaxel updates RSS · CI watch RSS
- Kyunghee University Medical Center portfolio CI
Frequently asked questions about Combination of SH003 and Docetaxel
What is Combination of SH003 and Docetaxel?
Combination of SH003 and Docetaxel is a Small molecule drug developed by Kyunghee University Medical Center.
Who makes Combination of SH003 and Docetaxel?
Combination of SH003 and Docetaxel is developed by Kyunghee University Medical Center (see full Kyunghee University Medical Center pipeline at /company/kyunghee-university-medical-center).
What development phase is Combination of SH003 and Docetaxel in?
Combination of SH003 and Docetaxel is in Phase 1.